Erratum: Tracking early decline in cognitive function in older individuals at risk for Alzheimer disease dementia: The Alzheimer's disease cooperative study cognitive function instrument (JAMA Neurology (2015) DOI:10.1001/jamaneurol.2014.3375);Tracking early decline in cognitive function in older individuals at risk for Alzheimer disease dementia: The Alzheimer's disease cooperative study cognitive function instrument the Alzheimer's disease cooperative study cognitive function instrument

JAMA Neurology

Volumn 72, Issue 4, 2015, Pages 446-454

  Amariglio, Rebecca E ^a,b   Donohue, Michael C ^c,d   Marshall, Gad A ^a   Rentz, Dorene M ^a   Salmon, David P ^d   Ferris, Steven H ^e   Karantzoulis, Stella ^e   Aisen, Paul S ^d   Sperling, Reisa A ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e NEW YORK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E4;

AGED; AGING; ALZHEIMER DISEASE; ARTICLE; COGNITIVE FUNCTION INSTRUMENT; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; FEMALE; HETEROZYGOTE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MENTAL DETERIORATION; MINI MENTAL STATE EXAMINATION; NEUROPSYCHOLOGICAL TEST; ONSET AGE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK FACTOR; SCORING SYSTEM; VERY ELDERLY; CLINICAL TRIAL (TOPIC); COGNITION DISORDERS; PATHOPHYSIOLOGY; RISK ASSESSMENT; STATISTICS AND NUMERICAL DATA;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CLINICAL TRIALS AS TOPIC; COGNITION DISORDERS; DISEASE PROGRESSION; FEMALE; HETEROZYGOTE; HUMANS; LONGITUDINAL STUDIES; MALE; NEUROPSYCHOLOGICAL TESTS; RISK ASSESSMENT;

EID: 84928159328     PISSN: 21686149     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaneurol.2015.0382     Document Type: Erratum

References (31)

1. Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3):280-292.
2. Sperling RA, Jack CR Jr, Aisen PS. Testing the right target and right drug at the right stage. Sci Transl Med. 2011;3(111):111cm33.
3. US Food and Drug Administration. Guidance for Industry: Alzheimer's Disease: Developing Drugs for the Treatment of Early Stage Disease (Draft Guidance). Silver Spring, MD: US Food and Drug Administration; 2013.
4. Donohue MC, Sperling RA, Salmon DP, et al Australian Imaging, Biomarkers, and Lifestyle Flagship Study of Ageing; Alzheimer's Disease Neuroimaging Initiative; Alzheimer's Disease Cooperative Study. The preclinical Alzheimer cognitive composite: measuring amyloid-related decline. JAMA Neurol. 2014;71(8):961-970.
5. Rentz DM, Parra Rodriguez MA, Amariglio R, Stern Y, Sperling R, Ferris S. Promising developments in neuropsychological approaches for the detection of preclinical Alzheimer's disease: a selective review. Alzheimers Res Ther. 2013;5(6):58.
6. Kozauer N, Katz R. Regulatory innovation and drug development for early-stage Alzheimer's disease. N Engl J Med. 2013;368(13):1169-1171.
7. Hohman TJ, Beason-Held LL, Lamar M, Resnick SM. Subjective cognitive complaints and longitudinal changes in memory and brain function. Neuropsychology. 2011;25(1):125-130.
8. Wang L, van Belle G, Crane PK, et al. Subjective memory deterioration and future dementia in people aged 65 and older. J Am Geriatr Soc. 2004;52(12):2045-2051.
9. Reisberg B, Shulman MB, Torossian C, Leng L, Zhu W. Outcome over seven years of healthy adults with and without subjective cognitive impairment. Alzheimers Dement. 2010;6(1):11-24.
10. Jessen F, Feyen L, Freymann K, et al. Volume reduction of the entorhinal cortex in subjective memory impairment. Neurobiol Aging. 2006;27(12):1751-1756.
11. Saykin AJ, Wishart HA, Rabin LA, et al. Older adults with cognitive complaints show brain atrophy similar to that of amnestic MCI. Neurology. 2006;67(5):834-842.
12. Amariglio RE, Becker JA, Carmasin J, et al. Subjective cognitive complaints and amyloid burden in cognitively normal older individuals. Neuropsychologia. 2012;50(12):2880-2886.
13. Jessen F, Amariglio RE, van Boxtel M, et al Subjective Cognitive Decline Initiative (SCD-I) Working Group. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. Alzheimers Dement. 2014;10(6):844-852.
14. Walsh SP, Raman R, Jones KB, Aisen PS; Alzheimer's Disease Cooperative Study Group. ADCS Prevention Instrument Project: the Mail-In Cognitive Function Screening Instrument (MCFSI). Alzheimer Dis Assoc Disord. 2006;20(4)(suppl 3):S170-S178.
15. Snitz BE, Yu L, Crane PK, Chang CC, Hughes TF, Ganguli M. Subjective cognitive complaints of older adults at the population level: an item response theory analysis. Alzheimer Dis Assoc Disord. 2012;26(4):344-351.
16. Gifford KA, Liu D, Lu Z, et al. The source of cognitive complaints predicts diagnostic conversion differentially among nondemented older adults. Alzheimers Dement. 2014;10(3):319-327.
17. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993; 43(11):2412-2414.
18. Teng EL, Chui HC. The Modified Mini-Mental State (3MS) examination. J Clin Psychiatry. 1987;48 (8):314-318.
19. Grober E, Merling A, Heimlich T, Lipton RB. Free and cued selective reminding and selective reminding in the elderly. J Clin Exp Neuropsychol. 1997;19(5):643-654.
20. Kluger A, Ferris SH, Golomb J, Mittelman MS, Reisberg B. Neuropsychological prediction of decline to dementia in nondemented elderly. J Geriatr Psychiatry Neurol. 1999;12(4):168-179.
21. Wechsler D. Wechsler Adult Intelligence Scale-Revised. San Antonio, TX: Psychological Corp; 1981.
22. Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004;256(3):183-194.
23. Shrout PE, Fleiss JL. Intraclass correlations: uses in assessing rater reliability. Psychol Bull. 1979; 86(2):420-428.
24. Mallinckrodt CH, Clark WS, David SR. Accounting for dropout bias using mixed-effects models. J Biopharm Stat. 2001;11(1-2):9-21.
25. Yesavage JA,Brink TL,Rose TL, et al. Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res. 1982-1983-1983;17(1):37-49.
26. Akaike H. A new look at the statistical model identification. IEEE Trans Automat Contr. 1974;19 (6):716-723.
27. Beckett LA, Tancredi DJ, Wilson RS. Multivariate longitudinal models for complex change processes. Stat Med. 2004;23(2):231-239.
28. Wolfsgruber S, Wagner M, Schmidtke K, et al. Memory concerns, memory performance and risk of dementia in patients with mild cognitive impairment. PLoS One. 2014;9(7):e100812.
29. Caselli RJ, Chen K, Locke DE, et al. Subjective cognitive decline: self and informant comparisons. Alzheimers Dement. 2014;10(1):93-98.
30. Gélinas I, Gauthier L, McIntyre M, Gauthier S. Development of a functional measure for persons with Alzheimer's disease: the disability assessment for dementia. Am J Occup Ther. 1999;53(5):471-481.
31. Galasko D, Bennett DA, Sano M, Marson D, Kaye J, Edland SD; Alzheimer's Disease Cooperative Study. ADCS Prevention Instrument Project: assessment of instrumental activities of daily living for community-dwelling elderly individuals in dementia prevention clinical trials. Alzheimer Dis Assoc Disord. 2006;20(4)(suppl 3):S152-S169.